Beacon introduces another new drug for Breast Cancer treatment.
Beacon introduces protein Tyrosine Kinase Inhibitor (TKI) Lapatinib under the brand name Lapanix (250 mg).
Capecitabine, for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress HER2 and who have received prior therapy including an anthracycline,a taxane and trastuzumab.
Letrozole for the treatment of postmenopausal women with hormone receptor positive metastaic breast cancer.
To know more visit our product website: www.lapanix.com